Date: 2017-10-04
Type of information: Establishment of a new subsidiary in the EU
Compound: cell and gene therapy products
Company: BioNTech (Germany) Eufets (Germany) BioNTech Innovative Manufacturing Services (Germany)
Therapeutic area: Technology - Services
Type agreement: establishment of a new subsidiary in the EU
Action mechanism: gene therapy/cell therapy
Disease:
Details:
- • On October 4, 2017, BioNTech, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, announced that its manufacturing subsidiary,EUFETS, has been re-branded as BioNTech Innovative Manufacturing Services.
- Furthermore, to prepare for further growth in response to increasing demand for cell and gene therapy products, in
particular for CAR-T and T-Cell immunotherapies, BioNTech Innovative Manufacturing Services will significantly increase its production capacity by doubling cleanroom space and expanding development and quality control areas in a new facility.
- BioNTech Innovative Manufacturing Services, based in Idar-Oberstein, Germany, is an experienced GMP-certified contract development and manufacturing organization, specializing in cell and gene therapy products such as viral vectors, cellular products and in vitro transcribed mRNA. For more than 20 years, it has supplied important cell and gene therapy medicinal products worldwide.
- The subsidiary is also responsible for the manufacturing of BioNTech´s proprietary, leading-edge mRNA immunotherapy programs including its individualized IVAC® cancer vaccines for clinical development, which is complemented by a second BioNTech mRNA manufacturing facility currently under construction at the Company´s headquarters in Mainz, Germany.
Financial terms:
Latest news:
Is general: Yes
